Get the Daily Brief
Latest Biotech News
Insilico splits NLRP3 rights — China deals and licensing cash
AI‑driven drug developer Insilico Medicine struck commercial agreements splitting rights to its preclinical, brain‑penetrant NLRP3 inhibitor, generating upfront payments and structured milestones...
GSK to buy Rapt for $2.2B — adds long‑acting anti‑IgE
GSK agreed to acquire Rapt Therapeutics for $2.2 billion to obtain ozureprubart, a long‑acting anti‑IgE monoclonal antibody currently in a Phase IIb prophylactic trial for food allergy. The...
Corvus’ atopic dermatitis pill... shares surge on phase I readout
Corvus Pharmaceuticals reported early clinical data showing robust activity for oral ITK inhibitor soquelitinib in atopic dermatitis, prompting a sharp market rally. The company said the latest...
Merck‑Moderna cancer vaccine sustains 49% risk cut at five years
Long‑term follow‑up shows Merck and Moderna’s personalized cancer vaccine continued to reduce the risk of recurrence or death by 49% at five years when added to Keytruda in melanoma patients, the...
Erasca upsized offering at $10 — raises $225M for RAS/MAPK programs
Erasca priced an upsized public offering of 22,500,000 shares at $10.00 per share, expected to generate about $225 million in gross proceeds to fund its clinical‑stage RAS/MAPK oncology programs....
CMS backs Illumina's TruSight test — $2,989.55 reimbursement set
The U.S. Centers for Medicare & Medicaid Services granted reimbursement for Illumina’s TruSight Oncology Comprehensive assay at $2,989.55 per test, effective Jan. 1, 2026, under PLA code 0543U....
Congress drafts Medicare pathway for MCED tests — coverage starts 2029
A provision in the current appropriations bill would create a Medicare coverage pathway for FDA‑approved multi‑cancer early detection (MCED) tests, with reimbursement modeled on the multi‑target...
Biomakers raises $8M — AI oncology platform to scale into Latin America
Biomakers raised $8 million from strategic and venture investors, including Labcorp Venture Fund and Oncology Ventures, to scale its AI‑enabled precision oncology platform and expand molecular...
CHO cells engineered to make amino acids — lower waste, simplify feeds
Researchers at the Technical University of Denmark engineered Chinese hamster ovary (CHO) cell lines that synthesize two essential amino acids (threonine and histidine) and lines that produce...
Quantum‑enabled proteins... engineered sensors reach living cells
A University of Oxford‑led team demonstrated that engineered proteins can exhibit optically detected magnetic resonance (ODMR) in living bacterial cells at room temperature, creating the first...
Astellas licenses MyoAAV capsid for XLMTM — low‑dose gene therapy enters clinic
Astellas Gene Therapies licensed Kate Therapeutics’ MyoAAV capsid and is developing ASP2957 (MyoAAV3.8‑MHCK7‑hMTM1) as a capsid‑engineered gene therapy for X‑linked myotubular myopathy (XLMTM)....
GSK pays $2.2B for Rapt: long‑acting food‑allergy bet
GSK agreed to acquire Rapt Therapeutics for $2.2 billion, taking ownership of ozureprubart, a long‑acting anti‑IgE monoclonal antibody in Phase IIb for food-allergy prophylaxis. The deal...
Pfizer exits ViiV stake: Shionogi expands HIV holdings
Pfizer is selling its minority stake in ViiV Healthcare to Shionogi, exiting a company it co‑founded with GSK in 2009. The move will shift ownership among existing minority shareholders while GSK...
Valneva pulls chikungunya from U.S.: safety probe prompts withdrawal
Valneva voluntarily withdrew its U.S. chikungunya vaccine application after the FDA placed a clinical hold linked to a newly reported serious adverse event outside the U.S. The company said the...
Medicare pivots on diagnostics: CMS pays Illumina test; MCED path emerges
Two developments moved diagnostic reimbursement and coverage: CMS granted Medicare reimbursement for Illumina’s TruSight Oncology Comprehensive assay at $2,989.55 per test, and a provision in the...
Merck‑Moderna vaccine holds at five years: durable melanoma benefit
Merck and Moderna reported sustained benefit from their personalized melanoma vaccine when added to Merck’s Keytruda, showing a continuing reduction in risk of recurrence or death at five years....
FDA agrees biomarker path for base editing: Beam wins accelerated route
Beam Therapeutics and FDA agreed that biomarkers evaluated over a year could support an accelerated approval application for BEAM‑302, Beam’s base‑editing candidate for alpha‑1 antitrypsin...
Corvus pill shocks markets: ITK inhibitor posts strong Phase I eczema data
Corvus Pharmaceuticals released Phase I data for soquelitinib, an oral ITK inhibitor, showing robust clinical activity in moderate‑to‑severe atopic dermatitis (AD). The cohort update demonstrated...
Tanabe pill clears Phase III: oral option for rare photodermatoses
Tanabe Pharma reported top‑line Phase III success for dersimelagon (MT‑7117), an oral melanocortin‑1 receptor agonist, in erythropoietic protoporphyria (EPP) and X‑linked protoporphyria (XLP). The...
Small biotechs advance: Boundless, Immunomic secure IND clearances
Boundless Bio received FDA IND clearance for BBI‑940, an oral kinesin degrader, with a first‑in‑human KOMODO‑1 trial for metastatic breast cancer planned in H1. Separately, Immunomic Therapeutics...